VivoSeq
Other

Hepatopulmonary Syndrome

9

Pipeline Programs↗

0

Active Trials↗

6

Companies Involved↗

Hepatopulmonary Syndrome is an early-stage landscape with 9 programs across 6 companies. The most active players are Takeda, Bayer, Novartis.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

0/100

Mech. Concentration

17/100

Completion Rate

33/100

Attrition Rate

40/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Takeda logo

Takeda

1 program

Phase 1Bayer logo

Bayer

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Phase 2V

Validus Pharmaceuticals

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

10

clinical trials

Terminated4 · 40%
Unknown status4 · 40%
Completed2 · 20%

Clinical Trials

Trial Activity

10 trials

A Pilot Study of Norfloxacin for Hepatopulmonary Syndrome
Completed·UUnity Health Toronto·Phase 2·NCT00362752·9 enrolled
Midodrine in Hepatopulmonary Syndrome
Completed·MMayo Clinic·Phase 1·NCT03600870·10 enrolled
Pilot Study of Pentoxifylline for Hepatopulmonary Syndrome
Terminated·UUniversity of Alabama at Birmingham·Phase 1·NCT00593658·9 enrolled
Sorafenib for Hepatopulmonary Syndrome
Terminated·UUniversity of Pennsylvania·Phase 2·NCT02021929·28 enrolled
Bosentan for Treatment of Hepatopulmonary Syndrome in Patients With Liver Cirrhosis
Terminated·MMedical University of Vienna·Phase 2·NCT01518595·6 enrolled
Letrozole in Patients With Hepatopulmonary Syndrome
Terminated·MMayo Clinic·Phase 2·NCT04577001·1 enrolled
Efficacy of Pentoxifylline and Rifaximin Combination in Pentoxifylline Refractory Clinical and Subclinical Hepatopulmonary Syndrome
Unknown status·IInstitute of Liver and Biliary Sciences, India·N/A·NCT01676597·80 enrolled
To Study the Safety and Efficacy of Simvastatin in Patients With Hepatopulmonary Syndrome in Cirrhosis.
Unknown status·IInstitute of Liver and Biliary Sciences, India·N/A·NCT05187715·45 enrolled
Analysis of Clinical Features of Chronic Liver Disease Complicated With Hepatopulmonary Syndrome
Unknown status·—·N/A·NCT05932927·500 enrolled
Efficacy and Safety of Pentoxifylline in Improving Oxygenation in Hepatopulmonary Syndrome
Unknown status·IInstitute of Liver and Biliary Sciences, India·N/A·NCT05373134·40 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)